Navigation Links
Better Treatment Found for Crohn's Disease
Date:4/14/2010

Two drugs aimed at taming overactive immune system worked best, study found

WEDNESDAY, April 14 (HealthDay News) -- Combination therapy with two drugs that control an unruly immune system provided the best relief yet seen for Crohn's disease, a condition in which the body mistakenly attacks its own intestinal tissue.

The new finding promises to change current treatment of Crohn's disease, said study leader Dr. William J. Sandborn, vice chair of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minn.

The results were reported in the April 15 issue of the New England Journal of Medicine.

Doctors now start treatment of Crohn's disease with steroids, Sandborn said. If the steroids do not provide relief from the abdominal pain, nausea, fever, weight loss, diarrhea and other symptoms of the condition, the next step is to use azathioprine, which reduces immune system activity broadly. Only if that fails will they try biologics, newer treatments that include monoclonal antibodies such as infliximab (Remicade). These drugs target a specific part of the immune system.

The trial showed that the azathioprine-alone step should be skipped. "This study suggests that the therapy that follows steroids should include a biologic," Sandborn added.

Therapy with both azathioprine and infliximab appears to be the treatment of choice if steroids are not effective, Sandborn said.

"What this trial shows is that the most effective strategy is combination therapy," he said.

The results will alter treatment of Crohn's disease to some extent, said Dr. Jeffrey A. Katz, a spokesman for the Crohn's and Colitis Foundation of America, but by and large "it really does confirm what other studies suggest and what is clinically apparent, that combination therapy is better than treatment with azathioprine alone."

"It will push me in the direction of using combination therapy a bit more than I have been," said Katz, an associate professor of medicine at Case Western University School of Medicine in Cleveland.

The international trial included 508 people with Crohn's disease who had never been treated with immunosuppressive drugs. One-third were given infliximab alone, one-third received only azathioprine and one-third were treated with both. The trial was funded by Centocor Ortho Biotech, which markets infliximab, and Schering-Plough.

After 26 weeks, 56.8 percent of those getting combination therapy had complete remission of symptoms, compared to 44.4 percent of those getting only infliximab and 30 percent of those getting only azathioprine.

The most worrisome problem with drugs that repress immune system activity is a severe infection. That problem occurred in 3.9 percent of the people who used combination therapy, 4.9 percent of those in the infliximab group and 5.6 percent of those in the azathioprine group, a difference that is not statistically significant, Sandborn said.

And because the combination therapy is more effective, it helps prevent infections that result from ulceration of the intestinal wall caused by Crohn's disease, he added.

Fear of side effects such as serious infections has held back use of the combination therapy, Katz said.

And while the study "answers our questions in a select group of patients," it does not fully resolve the safety issue, said Dr. Simon Lichtiger, an associate professor of gastroenterology at Mount Sinai Medical Center in New York City.

"The safety data aren't fully known and won't be known for a year," Lichtiger said. "It's not clear yet whether the advantages of the therapy exceed the possibility of long-term toxicity."

Crohn's disease is one of the two major forms of inflammatory bowel disease, whose underlying cause remains unclear. The other form is ulcerative colitis. An estimated 1 million Americans suffer from inflammatory bowel disease.

A similar study is underway in people with ulcerative colitis, Sandborn said. Results will not be available "for as much as a year or two," he noted.

More information

Crohn's disease and its treatment are described by the Crohn's and Colitis Foundation of America.



SOURCES: William J. Sandborn M.D., chair, gastroenterology and hepatology, Mayo Clinic, Rochester, Minn.; Jeffrey A. Katz, M.D., spokesman, Crohn's and Colitis Foundation of America; Simon Lichtiger, M.D., associate professor, gastroenterology, Mount Sinai Medical Center, New York City; April 15, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Flu Vaccine With Both B Strains May Offer Better Protection
2. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
3. Want better health information technology? Ask patients how they want it
4. Building a better flu vaccine: Add second strain of influenza B
5. Maintaining regular daily routines is associated with better sleep quality in older adults
6. Simple Forms Help Docs Do Better Breast Exams
7. My Health and Money Helps Consumers Stretch Their Healthcare Dollars and Make Better Choices
8. Discovery May Lead to Better Multiple Sclerosis Treatments
9. BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now
10. Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau
11. The American Heart Association's The Heart of Diabetes Campaign is Helping Patients 'Know Your Diabetes' Better
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... Farmingdale, NY (PRWEB) , ... May 26, 2016 ... ... and Hereditary Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on ... free to the public. , Dr. Maisel, founder of Retina Group of ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology: